Decreased levels of d-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia

Francesco Errico, Francesco Napolitano, Marta Squillace, Daniela Vitucci, Giuseppe Blasi, Andrea de Bartolomeis, Alessandro Bertolino, Antimo D'Aniello, Alessandro Usiello

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The potential implication of a decrease in the function of N-methyl-. d-aspartate receptors (NMDARs) in the pathophysiology of schizophrenia has long been hypothesised. Accordingly, compounds that inhibit the glycine-1 transporter or target the glycine-binding site of NMDARs, including the co-agonists d-serine and glycine, have shown promise in treating the symptoms of schizophrenia. Clinical interest for d-serine has also been supported by evidence for its abnormal metabolism in schizophrenic patients. Together with d-serine, another d-form amino acid, d-aspartate, exists in the brain of mammals. Synthesised by the enzyme aspartate racemase, d-aspartate is highly concentrated in the prenatal brain; after birth, its levels sharply decrease due to the catabolising activity of the enzyme d-aspartate oxidase. d-aspartate is able to stimulate NMDAR-dependent neurotransmission through direct action at the glutamate-binding site of NMDARs, thus functioning as an endogenous agonist for this subclass of glutamate receptors. In this study, we evaluated for the first time the content of d-aspartate and of its derivative, NMDA, in the post-mortem prefrontal cortex and striatum of schizophrenic patients. Moreover, in the same brain samples, we analysed the expression levels of the subunits that form NMDARs, which are the invivo targets of d-aspartate and NMDA. Interestingly, we found that d-aspartate and NMDA are consistently decreased in schizophrenia brains compared to control brains. In the prefrontal cortex, this decrease is correlated with a marked downregulation of NMDAR subunits. Overall, these results agree with the innovative therapeutic research in schizophrenia that is aimed at targeting glutamatergic transmission via d-amino acids.

Original languageEnglish
Pages (from-to)1432-1437
Number of pages6
JournalJournal of Psychiatric Research
Volume47
Issue number10
DOIs
Publication statusPublished - Oct 2013

Fingerprint

N-Methylaspartate
Prefrontal Cortex
Aspartic Acid
Schizophrenia
Serine
Brain
aspartate racemase
Glycine
Glycine Plasma Membrane Transport Proteins
Binding Sites
Therapeutic Human Experimentation
Amino Acids
Glutamate Receptors
Enzymes
Striatum
Synaptic Transmission
Glutamic Acid
Mammals
Oxidoreductases
Down-Regulation

Keywords

  • D-Aspartate
  • D-Serine
  • NMDA receptors
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Arts and Humanities (miscellaneous)

Cite this

Errico, F., Napolitano, F., Squillace, M., Vitucci, D., Blasi, G., de Bartolomeis, A., ... Usiello, A. (2013). Decreased levels of d-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia. Journal of Psychiatric Research, 47(10), 1432-1437. https://doi.org/10.1016/j.jpsychires.2013.06.013

Decreased levels of d-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia. / Errico, Francesco; Napolitano, Francesco; Squillace, Marta; Vitucci, Daniela; Blasi, Giuseppe; de Bartolomeis, Andrea; Bertolino, Alessandro; D'Aniello, Antimo; Usiello, Alessandro.

In: Journal of Psychiatric Research, Vol. 47, No. 10, 10.2013, p. 1432-1437.

Research output: Contribution to journalArticle

Errico, F, Napolitano, F, Squillace, M, Vitucci, D, Blasi, G, de Bartolomeis, A, Bertolino, A, D'Aniello, A & Usiello, A 2013, 'Decreased levels of d-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia', Journal of Psychiatric Research, vol. 47, no. 10, pp. 1432-1437. https://doi.org/10.1016/j.jpsychires.2013.06.013
Errico, Francesco ; Napolitano, Francesco ; Squillace, Marta ; Vitucci, Daniela ; Blasi, Giuseppe ; de Bartolomeis, Andrea ; Bertolino, Alessandro ; D'Aniello, Antimo ; Usiello, Alessandro. / Decreased levels of d-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia. In: Journal of Psychiatric Research. 2013 ; Vol. 47, No. 10. pp. 1432-1437.
@article{f9fc89287d114236b809bcea83096e0e,
title = "Decreased levels of d-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia",
abstract = "The potential implication of a decrease in the function of N-methyl-. d-aspartate receptors (NMDARs) in the pathophysiology of schizophrenia has long been hypothesised. Accordingly, compounds that inhibit the glycine-1 transporter or target the glycine-binding site of NMDARs, including the co-agonists d-serine and glycine, have shown promise in treating the symptoms of schizophrenia. Clinical interest for d-serine has also been supported by evidence for its abnormal metabolism in schizophrenic patients. Together with d-serine, another d-form amino acid, d-aspartate, exists in the brain of mammals. Synthesised by the enzyme aspartate racemase, d-aspartate is highly concentrated in the prenatal brain; after birth, its levels sharply decrease due to the catabolising activity of the enzyme d-aspartate oxidase. d-aspartate is able to stimulate NMDAR-dependent neurotransmission through direct action at the glutamate-binding site of NMDARs, thus functioning as an endogenous agonist for this subclass of glutamate receptors. In this study, we evaluated for the first time the content of d-aspartate and of its derivative, NMDA, in the post-mortem prefrontal cortex and striatum of schizophrenic patients. Moreover, in the same brain samples, we analysed the expression levels of the subunits that form NMDARs, which are the invivo targets of d-aspartate and NMDA. Interestingly, we found that d-aspartate and NMDA are consistently decreased in schizophrenia brains compared to control brains. In the prefrontal cortex, this decrease is correlated with a marked downregulation of NMDAR subunits. Overall, these results agree with the innovative therapeutic research in schizophrenia that is aimed at targeting glutamatergic transmission via d-amino acids.",
keywords = "D-Aspartate, D-Serine, NMDA receptors, Schizophrenia",
author = "Francesco Errico and Francesco Napolitano and Marta Squillace and Daniela Vitucci and Giuseppe Blasi and {de Bartolomeis}, Andrea and Alessandro Bertolino and Antimo D'Aniello and Alessandro Usiello",
year = "2013",
month = "10",
doi = "10.1016/j.jpsychires.2013.06.013",
language = "English",
volume = "47",
pages = "1432--1437",
journal = "Journal of Psychiatric Research",
issn = "0022-3956",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - Decreased levels of d-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia

AU - Errico, Francesco

AU - Napolitano, Francesco

AU - Squillace, Marta

AU - Vitucci, Daniela

AU - Blasi, Giuseppe

AU - de Bartolomeis, Andrea

AU - Bertolino, Alessandro

AU - D'Aniello, Antimo

AU - Usiello, Alessandro

PY - 2013/10

Y1 - 2013/10

N2 - The potential implication of a decrease in the function of N-methyl-. d-aspartate receptors (NMDARs) in the pathophysiology of schizophrenia has long been hypothesised. Accordingly, compounds that inhibit the glycine-1 transporter or target the glycine-binding site of NMDARs, including the co-agonists d-serine and glycine, have shown promise in treating the symptoms of schizophrenia. Clinical interest for d-serine has also been supported by evidence for its abnormal metabolism in schizophrenic patients. Together with d-serine, another d-form amino acid, d-aspartate, exists in the brain of mammals. Synthesised by the enzyme aspartate racemase, d-aspartate is highly concentrated in the prenatal brain; after birth, its levels sharply decrease due to the catabolising activity of the enzyme d-aspartate oxidase. d-aspartate is able to stimulate NMDAR-dependent neurotransmission through direct action at the glutamate-binding site of NMDARs, thus functioning as an endogenous agonist for this subclass of glutamate receptors. In this study, we evaluated for the first time the content of d-aspartate and of its derivative, NMDA, in the post-mortem prefrontal cortex and striatum of schizophrenic patients. Moreover, in the same brain samples, we analysed the expression levels of the subunits that form NMDARs, which are the invivo targets of d-aspartate and NMDA. Interestingly, we found that d-aspartate and NMDA are consistently decreased in schizophrenia brains compared to control brains. In the prefrontal cortex, this decrease is correlated with a marked downregulation of NMDAR subunits. Overall, these results agree with the innovative therapeutic research in schizophrenia that is aimed at targeting glutamatergic transmission via d-amino acids.

AB - The potential implication of a decrease in the function of N-methyl-. d-aspartate receptors (NMDARs) in the pathophysiology of schizophrenia has long been hypothesised. Accordingly, compounds that inhibit the glycine-1 transporter or target the glycine-binding site of NMDARs, including the co-agonists d-serine and glycine, have shown promise in treating the symptoms of schizophrenia. Clinical interest for d-serine has also been supported by evidence for its abnormal metabolism in schizophrenic patients. Together with d-serine, another d-form amino acid, d-aspartate, exists in the brain of mammals. Synthesised by the enzyme aspartate racemase, d-aspartate is highly concentrated in the prenatal brain; after birth, its levels sharply decrease due to the catabolising activity of the enzyme d-aspartate oxidase. d-aspartate is able to stimulate NMDAR-dependent neurotransmission through direct action at the glutamate-binding site of NMDARs, thus functioning as an endogenous agonist for this subclass of glutamate receptors. In this study, we evaluated for the first time the content of d-aspartate and of its derivative, NMDA, in the post-mortem prefrontal cortex and striatum of schizophrenic patients. Moreover, in the same brain samples, we analysed the expression levels of the subunits that form NMDARs, which are the invivo targets of d-aspartate and NMDA. Interestingly, we found that d-aspartate and NMDA are consistently decreased in schizophrenia brains compared to control brains. In the prefrontal cortex, this decrease is correlated with a marked downregulation of NMDAR subunits. Overall, these results agree with the innovative therapeutic research in schizophrenia that is aimed at targeting glutamatergic transmission via d-amino acids.

KW - D-Aspartate

KW - D-Serine

KW - NMDA receptors

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84881557265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881557265&partnerID=8YFLogxK

U2 - 10.1016/j.jpsychires.2013.06.013

DO - 10.1016/j.jpsychires.2013.06.013

M3 - Article

C2 - 23835041

AN - SCOPUS:84881557265

VL - 47

SP - 1432

EP - 1437

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

SN - 0022-3956

IS - 10

ER -